Key clinical point: Proteomic biomarkers were associated with event-free survival in chronic lymphocytic leukemia patients.
Major finding: Patients with high levels of sCD23 (P = .026), sCD27 (P = .04), SPINT1 (P = .001), and LY9 (P = .0003) had a shorter event-free survival.
Study details: Baseline serum samples of 51 chronic lymphocytic leukemia patients treated with chemoimmunotherapy were analyzed for 360 proteomic markers.
Disclosures: This research was supported by a grant from Gilead Sciences and an EU TRANSCAN/Dutch Cancer Society grant. The authors declared that they had no conflicts of interest.
Hosnijeh FS et al. Exp Hematol. 2020;89:55-60.